Skip to main content

Table 4 Associations of SNPs in PTGS1, PTGS2, ALOX12, ALOX15, ALOX5, and FLAP and their interactions with NSAID use with risk of colon cancer stratified by fat and FA intake

From: PTGS1, PTGS2, ALOX5, ALOX12, ALOX15, and FLAP SNPs: interaction with fatty acids in colon cancer and rectal cancer

Gene

SNP

Fatty acid

Genotype

No recent aspirin/NSAID use

Recent aspirin/NSAID use

Low

High

Low

High

ORa (95 % CI)

ORa (95 % CI)

ORa (95 % CI)

ORa (95 % CI)

ALOX12

rs11571339 (7,135 A > G)

n-3

AA

1

1.26 (1.01, 1.59)

1

0.93 (0.67, 1.29)

 

AG/GG

1.16 (0.84, 1.59)

0.81 (0.56, 1.18)

0.72 (0.45, 1.16)

1.02 (0.60, 1.73)

 

p-interaction (2-way)a

 

0.02

0.23

 
 

p-interaction (3-way)a

 

0.02

  

rs312462 (14,215 C > T)

SFA

GG

1

0.97 (0.76, 1.22)

1

1.41 (1.02, 1.96)

 

GA

0.72 (0.52, 0.99)

1.18 (0.84, 1.66)

1.32 (0.86, 2.04)

1.14 (0.71, 1.82)

L634L

 

AA

0.61 (0.18, 2.15)

0.63 (0.15, 2.56)

1.52 (0.35, 6.57)

1.02 (0.16, 6.31)

 

p-interaction (2-way)a

 

0.03

0.09

 
 

p-interaction (3-way)a

 

0.01

  

ALOX15

rs11568075 (305 C > T)

20:05

GG

1

0.80 (0.67, 0.97)

1

1 (0.77, 1.31)

 

GA/AA

0.71 (0.50, 1.01)

1.03 (0.71, 1.51)

1.89 (1.19, 2.99)

1.23 (0.75, 2.02)

 

p-interaction (2-way)a

 

0.02

0.21

 
 

p-interaction (3-way)a

 

0.02

  

FLAP

rs3803278 (8,663 T > C)

n-3

AA

1

1.2 (0.93, 1.55)

1

0.9 (0.63, 1.29)

 

AG

1.06 (0.82, 1.37)

1.2 (0.89, 1.61)

0.88 (0.63, 1.23)

0.94 (0.62, 1.41)

 

GG

1.04 (0.58, 1.87)

0.92 (0.53, 1.61)

0.38 (0.15, 0.94)

1.22 (0.55, 2.73)

 

p-interaction (2-way)a

 

0.46

0.08

 
 

p-interaction (3-way)a

 

0.048

  

rs9315053 (29,380 T > G)

18:02b

AA

1

1.42 (1.06, 1.90)

1

0.73 (0.49, 1.08)

 

AC

1.21 (0.95, 1.55)

1.21 (0.90, 1.61)

0.83 (0.59, 1.15)

0.95 (0.64, 1.41)

 

CC

1.3 (0.89, 1.91)

0.81 (0.52, 1.26)

0.7 (0.40, 1.23)

0.6 (0.28, 1.28)

 

p-interaction (2-way)a

 

0.003

0.17

 
 

p-interaction (3-way)a

 

0.01

  

FLAP

rs4293222 (2,034 C > G)

SFA

CC

1

1.01 (0.76, 1.36)

1

1.52 (1.02, 2.26)

 

CG

1.04 (0.80, 1.36)

1.08 (0.80, 1.45)

1.12 (0.78, 1.62)

1.3 (0.86, 1.97)

 

GG

0.94 (0.63, 1.41)

1.31 (0.86, 1.99)

1.59 (0.95, 2.67)

1.39 (0.78, 2.47)

 

p-interaction (2-way)a

 

0.36

0.11

 
 

p-interaction (3-way)a

 

0.04

  

rs17245197 (13,834 C > G)

PUFA

GG

1

1.05 (0.85, 1.30)

1

0.98 (0.72, 1.34)

 

GC/CC

0.89 (0.51, 1.56)

1.49 (0.78, 2.83)

2.19 (1.11, 4.34)

0.74 (0.30, 1.83)

 

p-interaction (2-way)a

 

0.28

0.06

 
 

p-interaction (3-way)a

 

0.03

  

Indel

23A/23A

 

1

1.01 (0.79, 1.28)

1

1.09 (0.78, 1.53)

23A/19A or 19A/19A

 

1.06 (0.81, 1.38)

1.35 (0.98, 1.85)

1.23 (0.85, 1.77)

0.83 (0.52, 1.31)

 

p-interaction (2-way)a

 

0.25

0.09

 
 

p-interaction (3-way)a

 

0.028

  

ALOX5

6pb VNTR

22:05

≥5/≥5

1

0.87 (0.71, 1.08)

1

1.11 (0.83, 1.48)

 

<5/≤5

0.77 (0.59, 1.00)

0.98 (0.75, 1.29)

1.28 (0.88, 1.84)

0.99 (0.69, 1.44)

 

p-interaction (2-way)a

 

0.042

0.18

 
 

p-interaction (3-way)a

 

0.029

  

22:06

≥5/≥5

1

0.78 (0.63, 0.97)

1

0.92 (0.68, 1.23)

 

<5/≤5

0.74 (0.57, 0.97)

0.92 (0.70, 1.21)

1.18 (0.82, 1.69)

0.88 (0.60, 1.28)

 

p-interaction (2-way)a

 

0.015

0.43

 
 

p-interaction (3-way)a

 

0.043

  
  1. Only SNPs with statistically significant interactions are shown
  2. Bold values are statistically significant
  3. aAdjusted for age, study center, ethnicity, sex, family history of disease, recent NSAID use (where appropriate), BMI, physical activity, dietary cholesterol, and caloric intake
  4. bThe same interaction was observed for rs9506352 (linkage disequilibrium r 2 = 0.9)